Drugs / Shouhui Tongbian Capsules
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07066059 | Aug 2025 → Mar 2027 expected | — | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07648394 | Aug → Dec 2026 expected | anus disorder, constipation disorder | China-Japan Friendship Hospital | Not yet recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07557394 | May 2026 → Nov 2027 expected | malignant pancreatic neoplasm | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06119880 | Nov 2023 → Dec 2024 | exocrine pancreatic insufficiency | Ruijin Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shouhui Tongbian Capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07648394 ↗ |
| Known as | Pancreatin Enteric-coated Capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06119880 ↗ |
| Modality | Protein / enzyme biologic | “pancreatic enzyme replacement therapy” NCT06119880 ↗ |
| Route | Oral | “Shouhui Tongbian Capsules are taken orally” NCT07557394 ↗ |